Pharmaceuticals
Pioneering the Future of Healthcare
At Quadri Pharma, our journey of excellence continues to evolve.
Building on our remarkable success in medical devices, consumables, IVF and life sciences, we are now embarking on an ambitious expansion into the pharmaceutical sector, bringing hope, innovation and advanced therapeutic solutions to patients who need them most.
A New Chapter in Specialized Care
We are strategically entering highly specialized therapeutic areas were unmet medical needs demand cutting-edge solutions.
Our focus encompasses:
- Oncology – Advancing cancer care with breakthrough treatments
- Hematology – Transforming blood disorder management
- Molecular Diagnostics – Enabling precision medicine through advanced testing
- Autoimmune Diseases – Addressing complex conditions including ALS and Multiple Sclerosis
- Chronic Kidney Disease – Supporting patients with comprehensive renal care solutions
- In Vitro Fertilization (IVF) – Providing innovative solutions for reproductive health
- Digital Therapeutics – Pioneering the future of healthcare technology
Strength Through Innovation
Our expansion is powered by a super-innovative portfolio that combines proven efficacy with next-generation science. We’re not just entering new markets; we’re reshaping them with solutions that make a real difference in patients’ lives.
Regional Excellence, Global Vision
With a robust regional expansion strategy, Quadri Pharma is establishing a strong presence across key markets, ensuring that advanced therapeutic options reach healthcare providers and patients wherever they are needed.
Find below the companies that offers a diverse range of pharmaceutical products:
Inhixa Techdow
The pharmaceutical industry is a highly regulated and competitive field.”
Introducing Inhixa the advanced Anticoagulant Solution for DVT Treatment and Prophylaxis
and the gold standard in Low Molecular Weight Heparin (LMWH) treatment for adults!
Inhixa by Techdow is empowering you on your journey towards a life free from
- Venous Thromboembolism (VTE)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
Techdow Pharma is revolutionizing the treatment of blood-clot-related conditions!
Inhixa by Techdow is the advanced Anticoagulant Solution for DVT treatment and prevention.
Inhixa reduces the risk of clots that could cause problems like heart attacks or strokes. Why choose Inhixa? Its proven effectiveness makes it a standout choice.
Available in a versatile range of concentrations — 150, 120, 100, 80, 60, 40, and 20 milligrams — Inhixa offers precise dosing and easy administration to meet every patient’s unique needs.
Each pack comes with 2 prefilled syringes (PFS), ensuring a seamless experience for healthcare providers and patients alike.
Produced by Techdow, a leader in the industry, Inhixa represents innovation and quality backed by cutting-edge research and development.
Since 1949, Kyowa Hakko Kirin (formerly known as Kyowa Hakko Kogyo) has been at the forefront of biotechnology and life sciences as an R&D-based company.
With special strengths in biotechnology, Kyowa Kirin and its Group companies are dedicated to enhancing health and well-being worldwide by creating new value through pioneering advances in life sciences and technologies.
Their operations encompass research, development, manufacturing, marketing, and the import/export of pharmaceuticals.
Neulasta Onpro
Why Neulasta Onpro? When chemotherapy-induced febrile neutropenia threatens your health, Neulastim provides the essential support you need.
By choosing Neulasta, you are opting for
- Reliability
- Efficacy
- Decreased risk of febrile neutropenia
- Resilience through your chemotherapy journey
Is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
One 6 mg dose (a single pre-filled syringe) of Neulasta is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.
Neulasta is injected subcutaneously. The injections should be given into the thigh, abdomen or upper arm.
CRYSViTA
What is CRYSViTA? It is the only FDA-approved treatment for X-Linked Hypophosphatemia (XLH) in adults and children 6 months of age or older!
Bringing you closer to a life with stronger bones!
XLH causes the body to lose phosphorus, which is an essential mineral for bone health. CRYSViTA, the solution for X-linked Hypophosphatemia, helps increase phosphorus levels in the body, restoring them to normal.
What is XHL?
- XLH patients’ bodies produce an excess of fibroblast growth factor 23 (FGF23).
- This excess of FGF23 causes the kidneys to release too much phosphorus through the urine.
- This increased release of phosphorus leads to lower levels in the body, which can weaken bones.
CRYSViTA helps XLH patients’ bodies hold onto phosphorus, consequently alleviating their symptoms and strengthening their bones!
Neopogen
Why Neopogen? It is the most reliable and effective way to manage persistent neutropenia and safeguard against bacterial infections!
How does it work?
- It selectively increases neutrophil in the blood, which are important for fighting infections caused by bacteria
- It increased neutrophil cells’ functional efficacy
Neopogen is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).
Neopogen is indicated for the treatment of persistent neutropenia
(ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. The recommended dose of Neopogen is 0.5 MU (5 mg)/kg/day. The first dose of Neopogen should be administered at least 24 hours after cytotoxic chemotherapy.
























